Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal K ATP channel

Eric R. Gross, Kasem Nithipatikom, Anna K. Hsu, Jason N. Peart, John R. Falck, William B. Campbell, Garrett J. Gross

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Inhibition of 20-hydroxyeicosatrienoic acid (20-HETE), by pretreatment with pharmacological inhibitors of cytochrome P450 (CYP) ω-hydroxylase, has been shown to reduce infarct size in canines when administered prior to ischemia. However, it is unknown whether these agents reduce infarct size when administered just prior to reperfusion and if the sarcolemmal and/or mitochondrial K ATP channels (sK ATP and mK ATP) contribute to cardioprotection. Therefore, we determined whether specific CYP inhibitors for epoxygenases and ω-hydroxylases are cardioprotective when given either prior to ischemia or prior to reperfusion and furthermore, if selective inhibition of the sK ATP by HMR-1098 or mK ATP by 5-hydroxydecanoic acid (5-HD) could abrogate this effect. Male Sprague-Dawley rats underwent 30 minutes of ischemia followed by 2 hours of reperfusion. Groups received either miconazole (MIC, non-selective CYP inhibitor, 3 mg/kg), 17-octadecynoic acid (17-ODYA, CYP ω-hydroxylase inhibitor, 0,3 or 3 mg/kg), N-methylsulfonyl-12, 12-dibromododec-11-enamide (DDMS, CYP ω-hydroxylase inhibitor, 0,4 or 4 mg/kg), N-methanesulfonyl-6-(2- propargyloxyphenyl)hexanamide (MS-PPOH, CYP epoxygenase inhibitor, 3 mg/kg), or vehicle either 10 minutes prior to ischemia or 5 minutes prior to reperfusion. Rats also received either HMR-1098 (6 mg/kg) or 5-HD (10 mg/kg) 10 minutes prior to reperfusion, with subsets of rats also receiving either MIC or 17-ODYA 5 minutes prior to reperfusion. DDMS and 17-ODYA dose dependently reduced infarct size. Rats treated with MIC, 17-ODYA and DDMS, but not MS-PPOH, produced comparable reductions in infarct size when administered prior to ischemia or reperfusion compared to vehicle. HMR-1098, but not 5-HD, also blocked the infarct size reduction afforded by MIC and 17-ODYA. These data suggest a novel cardioprotective pathway involving CYP ω-hydroxylase inhibition and subsequent activation of the sK ATP channel during reperfusion.

Original languageEnglish (US)
Pages (from-to)1245-1249
Number of pages5
JournalJournal of Molecular and Cellular Cardiology
Volume37
Issue number6
DOIs
StatePublished - Dec 2004

Fingerprint

Mixed Function Oxygenases
Cytochrome P-450 Enzyme System
Reperfusion
Adenosine Triphosphate
Ischemia
Miconazole
Sprague Dawley Rats
Canidae
Pharmacology
Acids
DDMS
HMR 1098
5-hydroxydecanoic acid

Keywords

  • 20-HETE
  • Cytochrome P450
  • Ischemia
  • K
  • Reperfusion

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal K ATP channel. / Gross, Eric R.; Nithipatikom, Kasem; Hsu, Anna K.; Peart, Jason N.; Falck, John R.; Campbell, William B.; Gross, Garrett J.

In: Journal of Molecular and Cellular Cardiology, Vol. 37, No. 6, 12.2004, p. 1245-1249.

Research output: Contribution to journalArticle

Gross, Eric R. ; Nithipatikom, Kasem ; Hsu, Anna K. ; Peart, Jason N. ; Falck, John R. ; Campbell, William B. ; Gross, Garrett J. / Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal K ATP channel. In: Journal of Molecular and Cellular Cardiology. 2004 ; Vol. 37, No. 6. pp. 1245-1249.
@article{2b221cdc132a44da92364a061ef42d49,
title = "Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal K ATP channel",
abstract = "Inhibition of 20-hydroxyeicosatrienoic acid (20-HETE), by pretreatment with pharmacological inhibitors of cytochrome P450 (CYP) ω-hydroxylase, has been shown to reduce infarct size in canines when administered prior to ischemia. However, it is unknown whether these agents reduce infarct size when administered just prior to reperfusion and if the sarcolemmal and/or mitochondrial K ATP channels (sK ATP and mK ATP) contribute to cardioprotection. Therefore, we determined whether specific CYP inhibitors for epoxygenases and ω-hydroxylases are cardioprotective when given either prior to ischemia or prior to reperfusion and furthermore, if selective inhibition of the sK ATP by HMR-1098 or mK ATP by 5-hydroxydecanoic acid (5-HD) could abrogate this effect. Male Sprague-Dawley rats underwent 30 minutes of ischemia followed by 2 hours of reperfusion. Groups received either miconazole (MIC, non-selective CYP inhibitor, 3 mg/kg), 17-octadecynoic acid (17-ODYA, CYP ω-hydroxylase inhibitor, 0,3 or 3 mg/kg), N-methylsulfonyl-12, 12-dibromododec-11-enamide (DDMS, CYP ω-hydroxylase inhibitor, 0,4 or 4 mg/kg), N-methanesulfonyl-6-(2- propargyloxyphenyl)hexanamide (MS-PPOH, CYP epoxygenase inhibitor, 3 mg/kg), or vehicle either 10 minutes prior to ischemia or 5 minutes prior to reperfusion. Rats also received either HMR-1098 (6 mg/kg) or 5-HD (10 mg/kg) 10 minutes prior to reperfusion, with subsets of rats also receiving either MIC or 17-ODYA 5 minutes prior to reperfusion. DDMS and 17-ODYA dose dependently reduced infarct size. Rats treated with MIC, 17-ODYA and DDMS, but not MS-PPOH, produced comparable reductions in infarct size when administered prior to ischemia or reperfusion compared to vehicle. HMR-1098, but not 5-HD, also blocked the infarct size reduction afforded by MIC and 17-ODYA. These data suggest a novel cardioprotective pathway involving CYP ω-hydroxylase inhibition and subsequent activation of the sK ATP channel during reperfusion.",
keywords = "20-HETE, Cytochrome P450, Ischemia, K, Reperfusion",
author = "Gross, {Eric R.} and Kasem Nithipatikom and Hsu, {Anna K.} and Peart, {Jason N.} and Falck, {John R.} and Campbell, {William B.} and Gross, {Garrett J.}",
year = "2004",
month = "12",
doi = "10.1016/j.yjmcc.2004.10.008",
language = "English (US)",
volume = "37",
pages = "1245--1249",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal K ATP channel

AU - Gross, Eric R.

AU - Nithipatikom, Kasem

AU - Hsu, Anna K.

AU - Peart, Jason N.

AU - Falck, John R.

AU - Campbell, William B.

AU - Gross, Garrett J.

PY - 2004/12

Y1 - 2004/12

N2 - Inhibition of 20-hydroxyeicosatrienoic acid (20-HETE), by pretreatment with pharmacological inhibitors of cytochrome P450 (CYP) ω-hydroxylase, has been shown to reduce infarct size in canines when administered prior to ischemia. However, it is unknown whether these agents reduce infarct size when administered just prior to reperfusion and if the sarcolemmal and/or mitochondrial K ATP channels (sK ATP and mK ATP) contribute to cardioprotection. Therefore, we determined whether specific CYP inhibitors for epoxygenases and ω-hydroxylases are cardioprotective when given either prior to ischemia or prior to reperfusion and furthermore, if selective inhibition of the sK ATP by HMR-1098 or mK ATP by 5-hydroxydecanoic acid (5-HD) could abrogate this effect. Male Sprague-Dawley rats underwent 30 minutes of ischemia followed by 2 hours of reperfusion. Groups received either miconazole (MIC, non-selective CYP inhibitor, 3 mg/kg), 17-octadecynoic acid (17-ODYA, CYP ω-hydroxylase inhibitor, 0,3 or 3 mg/kg), N-methylsulfonyl-12, 12-dibromododec-11-enamide (DDMS, CYP ω-hydroxylase inhibitor, 0,4 or 4 mg/kg), N-methanesulfonyl-6-(2- propargyloxyphenyl)hexanamide (MS-PPOH, CYP epoxygenase inhibitor, 3 mg/kg), or vehicle either 10 minutes prior to ischemia or 5 minutes prior to reperfusion. Rats also received either HMR-1098 (6 mg/kg) or 5-HD (10 mg/kg) 10 minutes prior to reperfusion, with subsets of rats also receiving either MIC or 17-ODYA 5 minutes prior to reperfusion. DDMS and 17-ODYA dose dependently reduced infarct size. Rats treated with MIC, 17-ODYA and DDMS, but not MS-PPOH, produced comparable reductions in infarct size when administered prior to ischemia or reperfusion compared to vehicle. HMR-1098, but not 5-HD, also blocked the infarct size reduction afforded by MIC and 17-ODYA. These data suggest a novel cardioprotective pathway involving CYP ω-hydroxylase inhibition and subsequent activation of the sK ATP channel during reperfusion.

AB - Inhibition of 20-hydroxyeicosatrienoic acid (20-HETE), by pretreatment with pharmacological inhibitors of cytochrome P450 (CYP) ω-hydroxylase, has been shown to reduce infarct size in canines when administered prior to ischemia. However, it is unknown whether these agents reduce infarct size when administered just prior to reperfusion and if the sarcolemmal and/or mitochondrial K ATP channels (sK ATP and mK ATP) contribute to cardioprotection. Therefore, we determined whether specific CYP inhibitors for epoxygenases and ω-hydroxylases are cardioprotective when given either prior to ischemia or prior to reperfusion and furthermore, if selective inhibition of the sK ATP by HMR-1098 or mK ATP by 5-hydroxydecanoic acid (5-HD) could abrogate this effect. Male Sprague-Dawley rats underwent 30 minutes of ischemia followed by 2 hours of reperfusion. Groups received either miconazole (MIC, non-selective CYP inhibitor, 3 mg/kg), 17-octadecynoic acid (17-ODYA, CYP ω-hydroxylase inhibitor, 0,3 or 3 mg/kg), N-methylsulfonyl-12, 12-dibromododec-11-enamide (DDMS, CYP ω-hydroxylase inhibitor, 0,4 or 4 mg/kg), N-methanesulfonyl-6-(2- propargyloxyphenyl)hexanamide (MS-PPOH, CYP epoxygenase inhibitor, 3 mg/kg), or vehicle either 10 minutes prior to ischemia or 5 minutes prior to reperfusion. Rats also received either HMR-1098 (6 mg/kg) or 5-HD (10 mg/kg) 10 minutes prior to reperfusion, with subsets of rats also receiving either MIC or 17-ODYA 5 minutes prior to reperfusion. DDMS and 17-ODYA dose dependently reduced infarct size. Rats treated with MIC, 17-ODYA and DDMS, but not MS-PPOH, produced comparable reductions in infarct size when administered prior to ischemia or reperfusion compared to vehicle. HMR-1098, but not 5-HD, also blocked the infarct size reduction afforded by MIC and 17-ODYA. These data suggest a novel cardioprotective pathway involving CYP ω-hydroxylase inhibition and subsequent activation of the sK ATP channel during reperfusion.

KW - 20-HETE

KW - Cytochrome P450

KW - Ischemia

KW - K

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=9644279413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644279413&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2004.10.008

DO - 10.1016/j.yjmcc.2004.10.008

M3 - Article

C2 - 15572055

AN - SCOPUS:9644279413

VL - 37

SP - 1245

EP - 1249

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 6

ER -